Sequential Paclitaxel Plus Cisplatin Chemotherapy and Radiotherapy as 1st Line Treatment for Esophageal Squamous Cell Cancer

Esophageal Squamous Cell Cancer Clinical Trial

Official title:
Sequential Paclitaxel Plus Cisplatin Chemotherapy and Radiotherapy as First Line Treatment for Metastatic Esophageal Squamous Cell Cancer:: a Phase II Single Center Prospective Clinical Trial

Status Recruiting

Clinical Trial Summary

Metastatic esophageal squamous cell carcinomas have poor prognosis and majority of patients resistant to chemotherapy in China. In the investigators phase II clinical trial proceeded before, the combination of paclitaxel with cisplatin showed good tolerance and efficacy to esophageal squamous cell carcinomas. Radiotherapy has been indicated as a definitive treatment for unresectable or medically inoperable tumors in ESCC patients. However, not only the combination with chemotherapy, but also the boundaries of the clinical target volume (CTV) are not internationally defined. The investigators then initiated a prospective phase II clinical trial with sequential paclitaxel/cisplatin and radiotherapy as the 1st line treatment in metastatic esophageal carcinoma to observe the efficacy and safety of the combination.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02016274
Study type	Interventional
Source	Peking University
Contact	Lin Shen, MD
Phone	86-10-88196561
Email	lin100@medmail.com.cn
Status	Recruiting
Phase	Phase 2
Start date	December 2013
Completion date	July 2016

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03223662` - Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy	Phase 2
Terminated	`NCT01627379` - Cisplatin and 5-FU +/- Panitumumab for Patients With Nonresectable,Advanced or Metastatic Esophageal Squamous Cell Cancer	Phase 3
Recruiting	`NCT01336049` - Nimotuzumab Plus Paclitaxel and Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer	Phase 2
Recruiting	`NCT05945823` - Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors	Phase 2
Recruiting	`NCT04804696` - Toripalimab With Paclitaxel and Cisplatin as Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma	Phase 2
Recruiting	`NCT02016287` - Sequential Paclitaxel Chemotherapy and Radiotherapy as 1st Line Treatment for Elderly Esophageal Squamous Cell Cancer	Phase 2
Active, not recruiting	`NCT01351103` - A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands	Phase 1
Recruiting	`NCT01993784` - Study of Nimotuzumab to Treat Esophageal Squamous Cell Carcinoma.	Phase 1/Phase 2